Safety Information

Revised: 26 October 2018

Early Warning System Monitoring Communications

Medicines and medical devices have important benefits in treating and preventing disease but can also cause side effects in some people.

This section contains communications issued by Medsafe for safety concerns with medicines and medical devices shortly after they have been identified. These safety concerns have not been fully investigated. These communications highlight potential safety concerns. The publication of monitoring communications is part of Medsafe's proactive approach to monitoring the safety of medicines and medical devices.

Further information on the criteria used by Medsafe to decide when to publish a monitoring communication (PDF 224 KB, 9 pages)

Safety concerns with monitoring communications have not been reviewed in detail. It is unknown if the safety concern(s) are linked to the medicine or medical device or are coincidental.

Medsafe emphasises that patients should NOT stop using any medicine or medical device subject to a monitoring communication. If you have any concerns with a medicine or medical device you are using, please contact your health professional. A monitoring communication does not mean that the medicine or medical device causes an adverse event.

Consumers are advised to use medicines and medical devices according to the instructions provided. For medicines, these are also outlined in the Consumer Medicine Information (CMI). For medical devices these are outlined in the instructions for use or user manual supplied with the medical device. Your healthcare professional can also provide help and assistance. Further information may be found on the product packaging or the company supplying the medicine or medical device may operate a helpline.

Healthcare professionals should not change a patient's treatment because of a monitoring communication.

It is likely that the some monitoring communication safety concerns will not result in any action being taken and the monitoring communication will be updated accordingly. If the Medsafe review of the safety concern concludes that there is a demonstrated link with a medicine or medical device an alert may be issued. Where required we will take appropriate action to improve the safe use of this medicine or medical device.

Monitoring Communications Issued in the Last Six Months

Date Medicine/Device Title
26 October 2018 Medicine M² Logo Possible risk of lichen planus or lichenoid drug eruption with zoster (shingles) vaccine or influenza vaccine
25 September 2018 Medicine M² Logo Update - Dabigatran and gout or gout-like symptoms
14 August 2018 Medicine M² Logo Isotretinoin and Obsessive Compulsive Disorder (OCD)
6 August 2018 Medicine Dolutegravir and the possible risk of neural tube defects when taken early in pregnancy
9 May 2018 Medicine Life-threatening severe allergic reaction (anaphylaxis) to Calocurb dietary supplement
30 April 2018 Medicine Beware turmeric/curcumin containing products can interact with warfarin

Archived list of monitoring communications

If you are aware of someone who may have experienced one of these safety concerns please report it. This helps Medsafe to investigate these safety concerns and decide if any action needs to be taken. Safety concerns for which Medsafe is seeking further reports are also highlighted with M² logo

Find out more about medicines monitoring M² logo

Further Information

Consumer question and answers on the early warning system

Information about the early warning system

Subscribe to receive Medsafe website update emails